Terumo Corporation reported record-high quarterly revenue of JPY311.8 billion, up 9% on a local currency basis, driven by strong global demand, particularly in the Americas. Operating profit surged 60% year-on-year to JPY89.5 billion, boosted by a JPY13 billion US tariff refund and JPY20 billion in one-time settlement proceeds, with adjusted operating profit up 35%. The Cardiac and Vascular company achieved 7% local currency revenue growth, led by strong demand for Transcatheter Heart Valve Systems and robust Neuro business performance, especially in China, Japan, and Europe. Full-year profit guidance was revised upward, incorporating the tariff refund and settlement proceeds, while the revenue outlook remained unchanged at JPY1.239 trillion, with expectations of record highs in both revenue and profit for fiscal year 2026.
Terumo CorporationRecord Q1 revenue and profit, raised full-year guidance, including one-time gains.
